Neoantigen is a patient-specific tumor antigen resulted from mutations during oncogenesis. Emerging data suggested that immune responsiveness against neoantigens correlated with the success of clinical tumor immunotherapies. Nowadays, the majority of studies on neoantigens have focused on MHC class I restricted antigens recognized by CD8+ T cells. With improved understanding of the underlying principles of tumor biology and immunology, increasing emphasis has been put on CD4+ T cells and MHC class II restricted antigens.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jiEHsE
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Consulting to Finance: How to Network, Tell Your Story, Spin Your Resume, and Dominate Your Investment Banking and Private Equity Interviews...
-
Abstract Purpose Pedicle screw malplacement, leading to neurological symptoms, vascular injury, and premature implant loosening, is not ...
-
Chromatin-based mechanisms offer therapeutic targets in acute myeloid leukemia (AML) that are of great current interest. In this study, we c...
-
A comparison of the academic performance and intelligence scores of asthmatic and nonasthmatic primary... A comparison of the academic perfo...
-
pubmed: cell cycle arrest[Effects of stachyine o... OncologyThe Movember Prostate Cancer Landscape A... pubmed: "int j surg case rep...
-
Abstract The ordered mesoporous silica SBA-15 has been applied in studies of ketorolac tromethamine adsorption and release. The SBA-15 mat...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου